Veopoz™ (pozelimab-bbfg) – New orphan drug approval
August 18, 2023 - The FDA announced the approval of Regeneron’s Veopoz (pozelimab-bbfg), for the treatment of adult and pediatric patients 1 year of age and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease.
Download PDF
